Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Biocorrx Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This activity is distributed across 1 distinct examiner and 1 distinct art unit. This concentration indicates that the company is not currently managing multiple simultaneous applications across different specialized groups at the patent office. For the practitioner, this means the current strategy is focused on the 1 distinct examiner within the Biotechnology & Pharmaceuticals sector.
The busiest examiner assigned to these matters is CHANDRAKUMAR, NIZAL S, who holds 1 busiest examiner pending office action. Given that the total number of pending office actions is 1, this specific examiner is responsible for the entire active Biotechnology & Pharmaceuticals workload. This structure means that the immediate prosecution strategy is tied to the feedback of this 1 examiner. The outcome of the 1 pending office action defines the status of the entire pending portfolio, requiring a focused response to the specific citations and rejections issued by CHANDRAKUMAR, NIZAL S.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270682 | Biodegradable Implant Including Naltrexone and Cholesterol | CHANDRAKUMAR, NIZAL S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270682 | Biodegradable Implant Including Naltrexone and Cholesterol | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270682 | Biodegradable Implant Including Naltrexone and Cholesterol | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiocorrx Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Biocorrx Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
